Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last hours
Enjoy this offer
* See conditions under "Our services"

Valuation: Active Biotech AB

Market Cap 161M 16.77M 14.62M 13.54M 12.68M 23.78M 1.58B 23.92M 62.27M 779M 62.96M 61.61M 2.7B P/E 2026 *
-
P/E 2027 * -
Enterprise Value 161M 16.77M 14.62M 13.54M 12.68M 23.78M 1.58B 23.92M 62.27M 779M 62.96M 61.61M 2.7B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
81.52%
Yield 2026 *
-
Yield 2027 * -
1 week-6.23%
Current month-2.95%
1 month-22.36%
3 months+51.62%
6 months+35.44%
Current year+32.50%
1 week 5.75
Extreme 5.75
6.59
1 month 5.3
Extreme 5.3
8.11
3 years 3.7
Extreme 3.7
52.95
5 years 3.7
Extreme 3.7
52.95
10 years 3.7
Extreme 3.7
427.11
Manager TitleAgeSince
Chief Executive Officer 64 01/07/2017
Director of Finance/CFO 75 01/01/2000
Chief Tech/Sci/R&D Officer - 01/01/2022
Director TitleAgeSince
Director/Board Member 70 07/04/2011
Chairman 61 23/05/2019
Director/Board Member 76 23/05/2019
Date Insider Type Main position Quantity % Market Cap.
25/01/21Buy

Director

24,261 -
25/01/21Buy

Director

525,000 -
25/01/21Buy

Director

935,000 -
Change 5-day change 1-year change 3-year change Capi.($)
+3.66%-0.41%-61.69%-76.03% 16.77M
+1.44%-1.25%+63.52%+114.88% 55.19B
+4.60%+3.02%+58.20%+47.16% 45.75B
-1.44%+0.39%-12.94%-19.24% 22.98B
-2.69%-2.10%-3.68%+379.00% 20.76B
+3.22%-0.84%+27.88%-34.00% 16.26B
+0.58%+1.08%+16.73%-38.06% 15.42B
-1.01%-2.30%+27.42%+171.92% 13.05B
+4.95%+11.70%+123.63%+252.19% 12.45B
+3.07%+0.14%+29.37% - 12.37B
Average +1.41%+2.23%+26.85%+88.65% 23.8B
Weighted average by Cap. +1.63%+1.48%+40.91%+99.90%

Financials

2026 *2027 *
Net sales - -
Net income -33.2M -3.47M -3.02M -2.8M -2.62M -4.91M -327M -4.94M -12.87M -161M -13.01M -12.73M -559M 18.2M 1.9M 1.66M 1.53M 1.44M 2.69M 179M 2.71M 7.05M 88.24M 7.13M 6.98M 306M
Net Debt - -
Logo Active Biotech AB
Active Biotech AB (publ) is a Sweden-based Company, which develops pharmaceutical products within medical areas where the immune defense is important, including cancer and inflammatory diseases. The project portfolio comprises both small, orally active immunomodulatory molecules and antibody-based immunotherapy.
Employees
-
Date Price Change Volume
18/06/26 6.095 kr +3.66% 49,259
17/06/26 5.880 kr +0.34% 70,725
16/06/26 5.860 kr -3.54% 60,595
15/06/26 6.075 kr -0.74% 103,709
12/06/26 6.120 kr -5.85% 98,574
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
B

Net sales - Rate of surprise

LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!